GAIS

Global AI Show 2024 Roaring Among Other Events in Dubai

Retrieved on: 
Monday, February 5, 2024

DUBAI, Feb 5, 2024 - (ACN Newswire) - As more speakers and attendees sign up for the grand Global AI Show 2024, the much-awaited event is waiting to explode its potential in April at Grand Hyatt Dubai.

Key Points: 
  • DUBAI, Feb 5, 2024 - (ACN Newswire) - As more speakers and attendees sign up for the grand Global AI Show 2024, the much-awaited event is waiting to explode its potential in April at Grand Hyatt Dubai.
  • Global AI Show 2024 is scheduled to be held at the luxurious Grand Hyatt Dubai from 16 to 17 April 2024, offering an exceptional opportunity to share ideas, uncover the potential of AI, and network in the ever-evolving AI sector.
  • VAP Group has also chosen an exquisite location for the after-party event on the popular White Beach Dubai with a breathtaking view and a chic outdoor setting.
  • With the expertise of the GAIS speakers, participants can gather valuable and unique knowledge and build perspective about the technology, ensuring everyone has useful experience from the Global AI Show.

Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines

Retrieved on: 
Thursday, November 30, 2023

Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s feet).

Key Points: 
  • Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s feet).
  • RelabotulinumtoxinA was well tolerated; the majority of patients did not experience any adverse events and there were no related serious adverse events reported.1
    43QM2107 is a phase IIIb, open-label, single-center study to assess aesthetic improvement of RelabotulinumtoxinA in patients with moderate to severe crow’s feet and frown lines.
  • By day two, 100% of patients noted improvement for crow’s feet and 96% noted improvement for frown lines.
  • For frown line severity, 32% of patients on day one and 92% of patients on day four received a score of zero or one.

Hyper.Train™, Hyper Intelligence Inc.'s Flagship Product, Emerges from Stealth to Deliver 30% Reduction in Costs for LLM and Generative AI Organizations

Retrieved on: 
Friday, November 10, 2023

NEW YORK, Nov. 10, 2023 /PRNewswire/ -- Hyper Intelligence, Inc. announces the launch of its flagship software product, Hyper.Train™, a proprietary, quantum-inspired algorithm that drastically enhances how Large Language Models (LLMs) operate on AI infrastructure.  Hyper.Train™ optimizes and removes redundancy within LLMs using three patented methods resulting in a reduction of the total cost of ownership for AI compute by at least 30% or more.  

Key Points: 
  • Hyper.Train™ optimizes and removes redundancy within LLMs using three patented methods resulting in a reduction of the total cost of ownership for AI compute by at least 30% or more.
  • "We believe that LLMs and GAIs can solve pressing global challenges," said Jason Turner, Chairman, Hyper Intelligence and CEO of Entanglement .
  • Inefficiencies in LLM and Generative AI (GAI) cost the largest service providers and companies hundreds of millions to billions of dollars per year.
  • Hyper.Train™ solves this challenge by utilizing quantum-inspired algorithms and proprietary techniques to reduce costs by 30% while improving compute capacity thereby allowing AI and LLM organizations to run larger, more efficient training models.

Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Cellulite

Retrieved on: 
Monday, December 19, 2022

SAN CLEMENTE, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices announced the U.S. Food and Drug Administration’s (FDA) clearance of Sofwave’s SUPERB™ technology to be used for the short-term improvement in the appearance of cellulite.

Key Points: 
  • Dr. Shimon Eckhouse, Chairman & Co-Founder commented on the occasion, “We are pleased to receive FDA clearance to use the Company's proprietary SUPERB™ technology to improve the appearance of cellulite in the short term.
  • Non-invasive treatment of cellulite is one of the most desired body treatments in medical aesthetics because of the high prevalence of cellulite in women of all ages and the lack of effective and safe solutions with no patient down-time.
  • “The FDA's clearance of SUPERB™ for use in cellulite could not have come at a timelier moment,” said Lou Scafuri, Sofwave's CEO.
  • In addition, the Sofwave SUPERB™ technology is also cleared by the U.S. FDA for a non-invasive dermatological aesthetic treatment to improve facial lines and wrinkles.

WeRide Launches the First Self-driving Robobus Test Ride in Saudi Arabia at 2022 Global AI Summit

Retrieved on: 
Monday, September 19, 2022

RIYADH, Saudi Arabia, Sept. 19, 2022 /PRNewswire/ --WeRide, a global leading company in autonomous driving, collaborated with the SaudiCompany for Artificial Intelligence (SCAI) to launch of the first dynamic display route of thedriverless robobus (WeRide Mini Robobus) at the 2022 Global AI Summit held in Riyadh, thecapital of Saudi Arabia.

Key Points: 
  • RIYADH, Saudi Arabia, Sept. 19, 2022 /PRNewswire/ --WeRide, a global leading company in autonomous driving, collaborated with the SaudiCompany for Artificial Intelligence (SCAI) to launch of the first dynamic display route of thedriverless robobus (WeRide Mini Robobus) at the 2022 Global AI Summit held in Riyadh, thecapital of Saudi Arabia.
  • This is the first fully driverless test ride of robobus in the Middle Eastcountry and it will take place from Sep. 19th to 22nd.
  • Previously, WeRide launched the first driverless public Robotaxi service in the Middle East in Abu Dhabi, capital of the United Arab Emirates.
  • The Global Artificial Intelligence Summit (GAIS) is a prominent global event organized by the Saudi Authority for Data and Artificial Intelligence (SDAIA).

Silk Medical Aesthetics Announces Feasibility Clinical Trial Results for its All-Natural Dermal Filler

Retrieved on: 
Wednesday, November 17, 2021

BOSTON, Nov. 17, 2021 /PRNewswire/ -- Silk Medical Aesthetics, alongside sister company Evolved by Nature, the developer of Activated Silk™ biotechnology, announced today the results of a 44-patient feasibility study under an FDA-approved IDE clinical trial for its all-natural dermal filler for Nasolabial Folds (NLFs). The ABOUT FACE™ BY NATURE dermal filler is designed to be biocompatible, biodegradable and reversible for soft tissue augmentation. The 13-week results demonstrate a favorable safety profile with high patient satisfaction and clinically meaningful improvement in NLF severity. The company also announced that it has received FDA-approval to initiate an IDE for a 50-patient feasibility clinical trial to study the product for lip volume enhancement and fine lines around the mouth—the trial has now been fully enrolled. This news coincides with former Allergan Aesthetics executive, Karina Guillen joining Evolved by Nature as their new VP of Regulatory Affairs.

Key Points: 
  • Silk Medical Aesthetics has created a next-generation dermal filler with lidocaine by enhancing the best features of hyaluronic acid with Activated Silk biotechnology.
  • BOSTON, Nov. 17, 2021 /PRNewswire/ -- Silk Medical Aesthetics, alongside sister company Evolved by Nature , the developer of Activated Silk biotechnology, announced today the results of a 44-patient feasibility study under an FDA-approved IDE clinical trial for its all-natural dermal filler for Nasolabial Folds (NLFs).
  • Silk Medical Aesthetics is a Boston-based company on a mission to create the next-generation dermal filler platform by leveraging the power of natural silk.
  • A sister company of biotechnology company Evolved by Nature, Silk Medical Aesthetics was founded by silk experts Drs.

Silk Medical Aesthetics Announces Feasibility Clinical Trial Results for its All-Natural Dermal Filler

Retrieved on: 
Wednesday, November 17, 2021

BOSTON, Nov. 17, 2021 /PRNewswire/ -- Silk Medical Aesthetics, alongside sister company Evolved by Nature , the developer of Activated Silk biotechnology, announced today the results of a 44-patient feasibility study under an FDA-approved IDE clinical trial for its all-natural dermal filler for Nasolabial Folds (NLFs).

Key Points: 
  • BOSTON, Nov. 17, 2021 /PRNewswire/ -- Silk Medical Aesthetics, alongside sister company Evolved by Nature , the developer of Activated Silk biotechnology, announced today the results of a 44-patient feasibility study under an FDA-approved IDE clinical trial for its all-natural dermal filler for Nasolabial Folds (NLFs).
  • The ABOUT FACE BY NATURE dermal filler is designed to be biocompatible, biodegradable and reversible for soft tissue augmentation.
  • Silk Medical Aesthetics is a Boston-based company on a mission to create the next-generation dermal filler platform by leveraging the power of natural silk.
  • A sister company of biotechnology company Evolved by Nature, Silk Medical Aesthetics was founded by silk experts Drs.